Pharmaceutical security market seen reaching $10.61 billion by 2030

The pharmaceutical security market is projected to grow from $5.6 billion in 2025 to $6.36 billion in 2026, driven by counterfeit drugs, stricter traceability rules and wider tracking technology use. The Business Research Company says the market could hit $10.61 billion by 2030 as pharma companies expand blockchain, AI, IoT and cybersecurity tools.

Why it matters: - Pharmaceutical security is becoming more central as counterfeit drugs, theft, tampering and diversion continue to threaten patient safety and supply chain trust. - The market's growth signals rising spending on serialization, traceability and monitoring systems that help pharma companies meet compliance demands and protect products from factory to patient.

What happened: - The Business Research Company published a Pharmaceutical Security Market Report 2026 covering market size, trends and global forecast from 2026 to 2035. - The report says the market will rise from $5.6 billion in 2025 to $6.36 billion in 2026, a 13.4% compound annual growth rate. - The report projects the market will reach $10.61 billion by 2030, with a 13.7% CAGR over the forecast period. - The report was released Sept. 10, 2026, from London. - Download a free sample of the report. - View the full pharmaceutical security market report.

The details: - Pharmaceutical security includes the technologies, systems and processes used to protect medicines across the supply chain. - The market's near-term growth is tied to counterfeit drug incidents, stricter rules for drug serialization and traceability, wider barcode tracking in pharma logistics, expanding pharmaceutical trade networks and greater pressure for supply chain transparency. - Longer-term growth is expected from blockchain adoption for traceability, AI for supply chain risk detection, IoT-enabled smart packaging and monitoring devices, digital compliance ecosystems and higher cybersecurity investment in distribution channels. - The report identifies key trends including serialization and track-and-trace systems, anti-counterfeiting packaging such as holograms and tamper-evident seals, cloud-based compliance management, smart packaging with embedded authentication and real-time diversion detection. - North America held the largest share of the market in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - Counterfeit drugs are no longer just a border-control or law-enforcement issue. They are now a core supply chain risk shaping technology spending across pharma logistics, packaging and compliance. - Public Health Wales reported in August 2024 that it identified 206 distinct substances, up from 185 in 2022–23. - Public Health Wales also said the proportion of diazepam samples containing other substances ranged from 39% in January 2024 to 55% in May 2023. - The report's emphasis on blockchain, AI and smart packaging suggests the market is moving from basic verification toward continuous, data-driven monitoring. - The 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, hotspots infographics and updated graphics and tables.

What's next: - Pharma companies are expected to increase investment in digital compliance systems, anti-counterfeiting packaging and real-time monitoring tools as regulations and counterfeit risks intensify. - The Asia-Pacific region is likely to capture more growth as pharmaceutical manufacturing expands and security technology adoption rises. - The Business Research Company is positioning the report as a planning tool for companies tracking market hotspots and future technology shifts.

The bottom line: - Pharmaceutical security is shifting from a niche safeguard to a core operating requirement for the global drug supply chain.